drugset / Trial / NCT03212807
Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL
Phase 2
Withdrawn
Singapore General Hospital
National Cancer Centre, Singapore · collabNational University Hospital, Singapore · collabRaffles Hospital, Singapore · collab
NaSingle-groupOpen-labelTreatment
Summary
PHASE II STUDY OF DURVALUMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY EBV ASSOCIATED SUBTYPES OF DLBCL, PRIMARY CNS LYMPHOMA AND PRIMARY TESTICULAR DLBCL Patients with relapsed refractory subtypes of DLBCL who fulfill the inclusion / exclusion criteria will be recruited to this trial and treated in this open label, phase 2 trial with the PDL1 inhibitor Durvalumab and Lenalidomide. The combination treatment will be given from the time of recruitment for 6 months when Lenalidomide will be stopped but Durvalumab will continue for a total of 2 years. Response will be assessed by PET / CT scans as per standard lugano criteria.
Timeline
- Start
- 2017-08
- Primary completion
- 2021-02
- Completion
- 2023-08
Outcome
Outcome not reported
Stopped: “FDA Hold for Combination Studies using Imids and PD1/PDL1 Compounds”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Lenalidomide | Other / unclassified | — | — |